Despite a strong opening, New York-based pharma giant Pfizer (NYSE: PFE) saw its shares fall in price over the morning on Tuesday, following the release of its financial results for the first quarter of 2023.
The drop comes after Pfizer reported revenues of $18.3 billion, well above analysts’ expectations, although the earnings per share (EPS) figure came in a little below many forecasts, at 97 cents.
Although it was expected, weak sentiment may have been driven by the continued decline in sales of the company’s blockbuster coronavirus products, leading to a 26% decrease in operational first quarter revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze